Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FLGT Stock Forecast 2026-2027
$18.68
Current Price
$530.52M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to FLGT Price Targets
+17.8%
To High Target of $22.00
-1.0%
To Median Target of $18.50
-19.7%
To Low Target of $15.00
FLGT Price Momentum
-2.5%
1 Week Change
+15.4%
1 Month Change
-9.7%
1 Year Change
-28.9%
Year-to-Date Change
-39.8%
From 52W High of $31.04
+38.8%
From 52W Low of $13.46
📊 TOP ANALYST CALLS
Did FLGT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fulgent is one of their latest high-conviction picks.
Latest FLGT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, FLGT has a neutral consensus with a median price target of $18.50 (ranging from $15.00 to $22.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $18.68, the median forecast implies a -1.0% downside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 19.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FLGT Analyst Ratings
1
Buy
1
Hold
0
Sell
FLGT Price Target Range
Low
$15.00
Average
$18.50
High
$22.00
Current: $18.68
Latest FLGT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FLGT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2026 | Piper Sandler | David Westenberg | Neutral | Reiterates | $15.00 |
| Nov 11, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Aug 5, 2025 | UBS | Buy | Upgrade | $N/A | |
| Aug 4, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| May 6, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| May 5, 2025 | Raymond James | Outperform | Reiterates | $N/A | |
| Mar 4, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Nov 11, 2024 | Piper Sandler | Neutral | Maintains | $N/A | |
| Mar 6, 2024 | Piper Sandler | Neutral | Maintains | $N/A | |
| Dec 7, 2023 | UBS | Neutral | Initiates | $N/A | |
| Oct 16, 2023 | Piper Sandler | Neutral | Maintains | $N/A | |
| Mar 2, 2023 | Credit Suisse | Outperform | Maintains | $N/A | |
| Dec 8, 2022 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Nov 18, 2022 | Raymond James | Outperform | Initiates | $N/A | |
| Nov 14, 2022 | Credit Suisse | Outperform | Maintains | $N/A | |
| Nov 14, 2022 | Piper Sandler | Overweight | Maintains | $N/A | |
| Aug 25, 2022 | Credit Suisse | Outperform | Initiates | $N/A | |
| May 16, 2022 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jan 25, 2022 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 10, 2021 | Credit Suisse | Underperform | Maintains | $N/A |
Fulgent Genetics Inc. (FLGT) Competitors
The following stocks are similar to Fulgent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FLGT
Fulgent Genetics
mkt cap
543.87M
Fulgent Genetics Inc. (FLGT) Financial Data
Fulgent Genetics Inc. has a market capitalization of $530.52M with a P/E ratio of -9.5x. The company generates $320.35M in trailing twelve-month revenue with a -23.0% profit margin.
Revenue growth is -3.2% quarter-over-quarter, while maintaining an operating margin of -45.0% and return on equity of -6.9%.
Valuation Metrics
Market Cap
$530.52M
Enterprise Value
$265.84M
P/E Ratio
-9.5x
PEG Ratio
-0.1x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
-3.2%
Gross Margin
+30.2%
Operating Margin
-45.0%
Net Margin
-23.0%
EPS Growth
-3.2%
Financial Health
Cash/Price Ratio
+52.1%
Current Ratio
5.3x
Debt/Equity
1.0x
ROE
-6.9%
ROA
-5.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fulgent Genetics Inc. (FLGT) Business Model
About Fulgent Genetics Inc.
What They Do
Provides genetic testing and precision medicine services.
Business Model
The company operates a laboratory services business that generates revenue through genetic testing and interpretation services provided to healthcare providers. It also has a therapeutic development segment focused on oncology, where it develops drug candidates aimed at improving cancer treatment outcomes.
Additional Information
Fulgent Genetics Inc. uses advanced technologies such as bioinformatics and AI-driven digital pathology to enhance its services. It primarily serves the U.S. market with accredited labs and has a strong focus on integrating diagnostics and therapeutics in the field of precision medicine.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,313
CEO
Mr. Ming Hsieh
Country
United States
IPO Year
2016
Website
www.fulgentgenetics.comFulgent Genetics Inc. (FLGT) Latest News & Analysis
Latest News
Quick Summary
Fulgent Genetics presented updated data on head and neck cancer at the ASCO 2026 Annual Meeting. The session is scheduled for June 4, 2026, in Chicago.
Why It Matters
Fulgent's presentation at ASCO 2026 could signal advancements in cancer research, potentially enhancing its market position and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for possible violations of federal securities laws, which may impact investors.
Why It Matters
The investigation into Fulgent Genetics for potential securities law violations may signal legal risks, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulgent Genetics (NASDAQ: FLGT) announced its abstract will be presented at the ASCO 2026 conference on June 1, 2026, during the Head and Neck Cancer Track session.
Why It Matters
Fulgent Genetics' presentation at ASCO 2026 highlights its advancements in oncology, potentially boosting investor confidence and impacting stock performance based on market reception and future prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Johnson Fistel, PLLP is investigating potential claims for Fulgent Genetics, Inc. (NASDAQ: FLGT) investors regarding possible losses linked to the company's executive officers under federal securities laws.
Why It Matters
The investigation into Fulgent Genetics could indicate potential legal troubles, impacting stock performance and investor confidence, which may lead to increased volatility and loss recovery concerns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
FoundationOne®PGx aids in selecting cancer therapies and dosing, promoting safer and more effective patient care.
Why It Matters
FoundationOne®PGx's role in optimizing cancer therapy enhances treatment efficacy, potentially increasing demand for the product and benefiting associated biotech firms' revenues and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Fulgent Genetics, Inc. (FLGT) held its Q1 2026 earnings call, providing updates on financial performance and strategic initiatives. Further details on results were discussed.
Why It Matters
Fulgent Genetics' Q1 2026 earnings call provides insights into its financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About FLGT Stock
What is Fulgent Genetics Inc.'s (FLGT) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Fulgent Genetics Inc. (FLGT) has a median price target of $18.50. The highest price target is $22.00 and the lowest is $15.00.
Is FLGT stock a good investment in 2026?
According to current analyst ratings, FLGT has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FLGT stock?
Wall Street analysts predict FLGT stock could reach $18.50 in the next 12 months. This represents a -1.0% decrease from the current price of $18.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fulgent Genetics Inc.'s business model?
The company operates a laboratory services business that generates revenue through genetic testing and interpretation services provided to healthcare providers. It also has a therapeutic development segment focused on oncology, where it develops drug candidates aimed at improving cancer treatment outcomes.
What is the highest forecasted price for FLGT Fulgent Genetics Inc.?
The highest price target for FLGT is $22.00 from at , which represents a 17.8% increase from the current price of $18.68.
What is the lowest forecasted price for FLGT Fulgent Genetics Inc.?
The lowest price target for FLGT is $15.00 from David Westenberg at Piper Sandler, which represents a -19.7% decrease from the current price of $18.68.
What is the overall FLGT consensus from analysts for Fulgent Genetics Inc.?
The overall analyst consensus for FLGT is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $18.50.
How accurate are FLGT stock price projections?
Stock price projections, including those for Fulgent Genetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 5:57 AM UTC